Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Technical420 Site Search

Returned 22 result(s).

6 Psychedelic Clinical Trials That Could Have A Major Impact On The Way We Address Mental Health

The psychedelic therapy market is one of the most exciting emerging industries and is a vertical that we are bullish on. The COVID pandemic has put a major emphasis on the value of mental health and we expect the psychedelic therapy industry to gain from this recognition. During the last…

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body. The trial will be conducted at the University Hospital Basel Liechti Lab, in Basel,…

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a…

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced an innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance, sleep quality, mood, neuroplasticity markers, emotion regulation, quality of life, and immune system response.…

5 Clinical Trials Leveraging Psychedelics That Investors Need To Be Watching

During the last year, we have seen a significant increase in the number of pre-clinical and clinical studies on psychedelic therapies and this is a trend that caught our attention. When most people think about the psychedelic industry, they tend to overlook the potential that is associated with the commercialization…

MindMed’s Drug Delivery Business Is One That Psychedelic Sector Investors Need To Be Watching

November has been a great month for the psychedelic therapy industry and was highlighted by Oregon passing legislation to decriminalize psychedelics. Although many people view the industry as not legitimate, the psychedelic therapy sector is comprised of real businesses that are funded and are working on developing treatments for debilitating…

MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has received a positive response on its protocol design for a Phase 2a clinical trial evaluating microdoses of LSD in the treatment of adult ADHD from the Swiss and Dutch health authorities. MindMed has also successfully submitted a…

MindMed Is Setting The Pace For Top Tier Psychedelics Stocks

MindMed (NEO: MMED, OTCQB: MMEDF) is considered to be one of the top psychedelic therapy biotech companies and is an opportunity that our readers should be aware of. Last week, the psychedelic therapy biotech company recorded volatile price movements after raising more than $28 million (CAD) through a private placement…

MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD

MindMed (NEO: MMED,OTCQB: MMEDF), the leading psychedelic medicine biotech company in partnership with University Hospital Basel's Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose dependent effects of LSD. The completed Phase 1 study will help MindMed in dose-finding and the planning of future Phase…

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) is pleased to announce that further to its previously announced offering, it has filed a final short form prospectus with the securities commissions or similar authorities in each province of Canada, other than Québec. Pursuant to the underwriting agreement with Canaccord Genuity…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link